Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Wave Life Sciences (WVE) EBITDA: 2013-2024

Historic EBITDA for Wave Life Sciences (WVE) over the last 12 years, with Dec 2024 value amounting to -$97.1 million.

  • Wave Life Sciences' EBITDA rose 12.62% to -$53.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$122.0 million, marking a year-over-year increase of 14.40%. This contributed to the annual value of -$97.1 million for FY2024, which is 68.63% down from last year.
  • Wave Life Sciences' EBITDA amounted to -$97.1 million in FY2024, which was down 68.63% from -$57.6 million recorded in FY2023.
  • In the past 5 years, Wave Life Sciences' EBITDA ranged from a high of -$57.6 million in FY2023 and a low of -$162.0 million during FY2022.
  • For the 3-year period, Wave Life Sciences' EBITDA averaged around -$105.6 million, with its median value being -$97.1 million (2024).
  • As far as peak fluctuations go, Wave Life Sciences' EBITDA soared by 64.45% in 2023, and later tumbled by 68.63% in 2024.
  • Yearly analysis of 5 years shows Wave Life Sciences' EBITDA stood at -$149.8 million in 2020, then rose by 18.25% to -$122.5 million in 2021, then plummeted by 32.32% to -$162.0 million in 2022, then surged by 64.45% to -$57.6 million in 2023, then tumbled by 68.63% to -$97.1 million in 2024.